Description

Aminosalicylate Sodium (CAS: 6018-19-5) is a high-purity pharmaceutical compound with the molecular formula C₇H₁₀NNaO₅, primarily used as an antimicrobial agent. This sodium salt derivative of 4-aminosalicylic acid is supplied as a dihydrate, ensuring stability and solubility for research and formulation applications. It meets stringent pharmacopeial standards (USP, EP) and is available as a certified reference material (CRM) for analytical and quality control purposes. Ideal for tuberculosis research, this compound exhibits bacteriostatic properties by inhibiting folate synthesis in Mycobacterium tuberculosis. Each batch is rigorously tested for identity, purity (≥97%), and water content, with detailed Certificates of Analysis (CoA) provided. Packaged in amber glass vials under inert atmosphere to prevent degradation.

Properties

• CAS Number: 6018-19-5
• Complexity: 165
• IUPAC Name: sodium;4-amino-2-hydroxy-benzoate;dihydrate
• InChI: InChI=1S/C7H7NO3.Na.2H2O/c8-4-1-2-5(7(10)11)6(9)3-4;;;/h1-3,9H,8H2,(H,10,11);;2*1H2/q;+1;;/p-1
• InChI Key: GMUQJDAYXZXBOT-UHFFFAOYSA-M
• Exact Mass: 211.04566670
• Molecular Formula: C7H10NNaO5
• Molecular Weight: 211.15
• SMILES: C1=CC(=C(C=C1N)O)C(=O)[O-].O.O.[Na+]
• Topological: 88.4
• Monoisotopic Mass: 211.04566670
• Physical Description: Beige crystalline solid;
• Synonyms: 6018-19-5, Parasal sodium, Pamisyl sodium, Sodium aminosalicylate, AMINOSALICYLATE SODIUM, TEEBACIN, Nemasol sodium, Paramisan sodium, Sodium P.A.S., Sodium Aminosalicylate Dihydrate, P.A.S. SODIUM, Para-aminosodium salicylate, UNII-S38B9W6AXW, S38B9W6AXW, Monosodium 4-aminosalicylate dihydrate, NSC-755862, Aminosalicylate sodium (USP), Aminosalicylate sodium [USP], Passodico, Sodiopas, Nippas, Pasade, Pasnal, Salvis, Pasalon-rakeet, Natri-pas, NSC 755862, PAS-Na, NEOPASALATE COMPONENT AMINOSALICYLATE SODIUM, 4-aminosalicylate sodium, UNII-T9ZKL3TNQF, para-aminosalicylate sodium, AMINOSALICYLATE SODIUM (USP IMPURITY), AMINOSALICYLATE SODIUM [USP IMPURITY], EINECS 205-091-2, Monosodium 4-amino-2-hydroxybenzoate, ANHYDROUS SODIUM AMINOSALICYLATE, Monosodium T4-amino-2-hydroxybenzoate, SODIUM AMINOSALICYLATE (MART.), SODIUM AMINOSALICYLATE DIHYDRATE (MART.), SODIUM AMINOSALICYLATE DIHYDRATE [MART.], SODIUM AMINOSALICYLATE DIHYDRATE (EP MONOGRAPH), SODIUM AMINOSALICYLATE DIHYDRATE [EP MONOGRAPH], ANHYDROUS SODIUM AMINOSALICYLATE (MART.), AMINOSALICYLATE SODIUM COMPONENT OF NEOPASALATE, Sodium 4-aminosalicylate dihydrate, sodium 4-amino-2-hydroxybenzoate dihydrate, Benzoic acid, 4-amino-2-hydroxy-, monosodium salt, dihydrate, 4-Aminosalicylic acid sodium salt dihydrate, Aminacyl, Sodium 4-aminosalicylate (dihydrate), MFCD00151044, 4-Aminosalicylic acid (sodium salt dihydrate), C7H10NNaO5, 4-Amino-salicylic acid sodium salt, Parasal sodium (TN), AMINOSALYLE SODIUM, SCHEMBL84166, aminosalicylate sodium dihydrate, HY-I0447AR, Natrium-p-Aminosalicylatdihydrat, CHEMBL2096646, DTXSID5036638, HY-I0447A, sodium p aminosalicylate dihydrate, Sodium p-aminosalicylate dihydrate, CS-M3079, AMINOSALICYLATE SODIUM [VANDF], p-Aminosalicylic Acid Monosodium Salt, AKOS024258376, FA32507, AS-11771, DA-67662, SY057407, PARA-AMINOSODIUM SALICYLATE [VANDF], sodium;4-amino-2-hydroxybenzoate;dihydrate, AMINOSALICYLATE SODIUM [ORANGE BOOK], p-Aminosalicylate acid sodium salt dihydrate, ST51038525, D00875, D78312, SODIUM AMINOSALICYLATE DIHYDRATE [VANDF], EN300-1265444, Sodium 4-aminosalicylate (dihydrate) (Standard), SODIUM AMINOSALICYLATE DIHYDRATE [WHO-DD], Sodium 4-aminosalicylate dihydrate, >=97.0% (T), Q27288525, F1905-7110, Sodium Aminosalicylate dihydrate for equipment qualification, 4-amino-2-hydroxybenzoic acid, sodium salt, hydrate, hydrate, Benzoic acid, 4-amino-2-hydroxy-, sodium salt, hydrate (1:1:2), Sodium aminosalicylate dihydrate, European Pharmacopoeia (EP) Reference Standard, Sodium aminosalicylate dihydrate for equipment qualification, European Pharmacopoeia (EP) Reference Standard, Sodium Aminosalicylate Dihydrate, Pharmaceutical Secondary Standard; Certified Reference Material

Aminosalicylate Sodium is a second-line antitubercular agent used in combination therapies for drug-resistant TB. It disrupts bacterial folate metabolism by competitively inhibiting dihydrofolate synthase. Research applications include studying mycobacterial resistance mechanisms and evaluating synergistic effects with rifampicin or isoniazid. Also employed as a USP/EP reference standard for HPLC method validation in pharmaceutical QC labs.

Safety and Hazards

GHS Hazard Statements

• H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
• H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
• H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

Precautionary Statements

• P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501

Hazard Classes and Categories

• Skin Irrit. 2 (100%)
• Eye Irrit. 2A (100%)
• STOT SE 3 (100%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.